A comprehensive view of Cellectis S.A.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.
AstraZeneca partners with biotech company Cellectis to leverage its gene editing technologies to develop up to 10 novel cell and gene therapy candidate products; AstraZeneca to initially invest US$105.0M in Cellectis
Published:
November 01, 2023
by AstraZeneca AB
|
Ask us about our Health Care Sector market view